Neuroprotective and cardioprotective conopeptides: An emerging class of drug leads

Current Opinion in Drug Discovery and Development

Volumn 12, Issue 2, 2009, Pages 231-239

  Twede, V D ^a   Miljanich, G ^b   Olivera, B M ^a   Bulaj, G ^a  

^a UNIVERSITY OF UTAH   (United States)

^b Airmid LLC   (United States)

Author keywords

Analgesic; Cardioprotection; Conopeptide; Conotoxin; Neuroprotection

Indexed keywords

CONANTOKIN; CONANTOKIN G; CONANTOKIN L; CONANTOKIN PR1; CONANTOKIN PR2; CONANTOKIN PR3; CONANTOKIN R; CONANTOKIN T; CONOPEPTIDE; DIZOCILPINE; KAPPA CONOTOXIN; KAPPA CONOTOXIN M RIIIJ; KAPPA CONOTOXIN M RIIIK; KAPPA CONOTOXIN PVIIA; MU CONOTOXIN; MU CONOTOXIN KIIIA; MU CONOTOXIN SIIIA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OMEGA CONOTOXIN; OMEGA CONOTOXIN MVIIA; OMEGA CONOTOXIN TVIA; SNAIL VENOM; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED POTASSIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL;

ANEURYSM SURGERY; BRAIN INFARCTION SIZE; BRAIN INJURY; CONTINUOUS INFUSION; CONUS SNAIL; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; EPILEPSY; HEART PROTECTION; HUMAN; HYPOTENSION; ISCHEMIC HEART DISEASE; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; PAIN; REVIEW; SNAIL; STRUCTURE ACTIVITY RELATION; TRAUMATIC BRAIN INJURY;

ANIMALS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR AGENTS; CONOTOXINS; DRUG DISCOVERY; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; NEUROPROTECTIVE AGENTS; OMEGA-CONOTOXINS; POTASSIUM CHANNEL BLOCKERS; RECEPTORS, N-METHYL-D-ASPARTATE; SODIUM CHANNEL BLOCKERS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 62149122662     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Olivera BM, Teichert RW: Diversity of the neurotoxic Conus peptides: A model for concerted pharmacological discovery. Mol Interv (2007) 7(5):251-260.
2. Han TS, Teichert RW, Olivera BM, Bulaj G: Conus venoms - a rich source of peptide-based therapeutics. Curr Pharm Des (2008) 14(24):2462-2479.
3. Teichert RW, Jimenez EC, Twede V, Watkins M, Hollmann M, Bulaj G, Olivera BM: Novel conantokins from Conus parius venom are specific antagonists of N-methyl-D-aspartate receptors. J Biol Chem (2007) 282(51):36905-36913. • The first example of a successful application of the phylogenetic analysis to discover new members of the conantokin family of Conus peptides. This strategy is likely to result in the identification of many new neuroprotective compounds that act via NMDA receptors.
4. Miljanich GP: Ziconotide: Neuronal calcium channel blocker for treating severe chronic pain. Curr Med Chem (2004) 11(23):3029-3040.
5. Ellison M, Olivera BM: α4/3 Conotoxins: Phylogenetic distribution, functional properties, and structure-function insights. Chem Rec (2007) 7(6):341-353.
6. Valentino K, Newcomb R, Gadbois T, Singh T, Bowersox SS, Bitner S, Justice A, Yamashiro D, Hoffman BB, Ciaranello R, Miljanich G et al: A selective N-type calcium channel antagonist protects against neuronal loss after global cerebral ischemia. Proc Natl Acad Sci USA (1993) 90(16):7894-7897.
7. Newcomb R, Abbruscato TJ, Singh T, Nadasdi L, Davis TP, Miljanich G: Bioavailability of ziconotide in brain: Influx from blood, stability, and diffusion. Peptides (2000) 21(4):491-501.
8. 2+-channel blocker prevents CA1 injury 24 h following severe brain forebrain ischemia and reduces infarction following focal ischemia. J Cereb Blood Flow Metab (1994) 14(6):903-910.
9. Bowersox SS, Singh T, Nadasdi L, Zukowska-Grojec Z, Valentino K, Hoffman BB: Cardiovascular effects of ω-conopeptides in conscious rats: Mechanisms of action. J Cardiovasc Pharmacol (1992) 20(5):756-764.
10. Colbourne F, Li H, Buchan AM: Continuing postischemic neuronal death in CA1: Influence of ischemia duration and cytoprotective doses of NBQX and SNX-111 in rats. Stroke (1999) 30(3):662-668.
11. Perez-Pinzon MA, Yenari MA, Sun GH, Kunis DM, Steinberg GK: SNX-111, a novel, presynaptic N-type calcium channel antagonist, is neuroprotective against focal cerebral ischemia in rabbits. J Neurol Sci (1997) 153(1):25-31.
12. Yenari MA, Palmer JT, Sun GH, de Crespigny A, Mosely ME, Steinberg GK: Time-course and treatment response with SNX-111, an N-type calcium channel blocker, in a rodent model of focal cerebral ischemia using diffusion-weighted MRI. Brain Res (1996) 739(1-2):36-45.
13. Zhao Q, Smith M-L, Siesjö BK: The ω-conotoxin SNX111, an N-type calcium channel blocker, dramatically ameliorates brain damage due to transient focal ischaemia. Acta Physiol Scand (1994) 150(4):459-461.
14. Takizawa S, Matsushima K, Fujita H, Nanri K, Ogawa S, Shinohara Y: A selective N-type calcium channel antagonist reduces extracellular glutamate release and infarct volume in focal cerebral ischemia. J Cereb Blood Flow Metab (1995) 15(4):611-618.
15. Burns LH, Jin Z, Bowersox SS: The neuroprotective effects of intrathecal administration of the selective N-type calcium channel blocker ziconotide in a rat model of spinal ischemia. J Vasc Surg (1999) 30(2):334-343.
16. Verweij BH, Muizelaar JP, Vinas FC, Peterson PL, Xiong Y, Lee CP: Mitochondrial dysfunction after experimental and human brain injury and its possible reversal with a selective N-type calcium channel antagonist (SNX-111). Neurol Res (1997) 19(3):334-339.
17. Samii A, Badie H, Fu K, Luther RR, Hovda DA: Effects of an N-type calcium channel antagonist (SNX 111; ziconotide) on calcium-45 accumulation following fluid-percussion injury. J Neurotrauma (1999) 16(10):879-892.
18. Lee LL, Galo E, Lyeth BG, Muizelaar JP, Berman RF: Neuroprotection in the rat lateral fluid percussion model of traumatic brain injury by SNX-185, an N-type voltage-gated calcium channel blocker. Exp Neurol (2004) 190(1):70-78.
19. Verweij BH, Muizelaar JP, Vinas FC, Peterson PL, Xiong Y, Lee CP: Improvement in mitochondrial dysfunction as a new surrogate efficiency measure for preclinical trials: Dose-response and time-window profiles for administration of the calcium channel blocker ziconotide in experimental brain injury. J Neurosurg (2000) 93(5):829-834.
20. Berman RF, Verweij BH, Muizelaar JP: Neurobehavioral protection by the neuronal calcium channel blocker ziconotide in a model of traumatic diffuse brain injury in rats. J Neurosurg (2000) 93(5):821-828.
21. Xiong Y, Peterson PL, Verweij BH, Vinas FC, Muizelaar JP, Lee CP: Mitochondrial dysfunction after experimental traumatic brain injury: Combined efficacy of SNX-111 and U-101033E. J Neurotrauma (1998) 15(7):531-544.
22. McGuire D, Bowersox S, Fellmann JD, Luther RR: Sympatholysis after neuron-specific, N-type, voltage-sensitive calcium channel blockade: First demonstration of N-channel function in humans. J Cardiovasc Pharmacol (1997) 30(3):400-403.
23. Olivera BM, McIntosh JM, Clark C, Middlemas D, Gray WR, Cruz LJ: A sleep-inducing peptide from Conus geographus venom. Toxicon (1985) 23(2):277-282.
24. Armstrong H, Zhou LM, Layer RT, Nielsen J, McCabe RT, White HS: Anticonvulsant profile of conantokin-G (con-G): A novel, broad-spectrum NMDA antagonist. Epilepsia (1998) 39(Suppl 6):Abs 2.031.
25. Malmberg AB, Gilbert H, McCabe RT, Basbaum AI: Powerful antinociceptive effects of the cone snail venom-derived subtype-selective NMDA receptor antagonists conantokins G and T. Pain (2003) 101(1-2):109-116.
26. Williams AJ, Dave JR, Phillips JB, Lin Y, McCabe RT, Tortella FC: Neuroprotective efficacy and therapeutic window of the high-affinity N-methyl-D-aspartate antagonist conantokin-G: In vitro (primary cerebellar neurons) and in vivo (rat model of transient focal brain ischemia) studies. J Pharmacol Exp Ther (2000) 294(1):378-386.
27. Donevan SD, McCabe RT: Conantokin-G is an NR2B-selective competitive antagonist of N-methyl-D-aspartate receptors. Mol Pharmacol (2000) 58(3):614-623.
28. Klein RC, Prorok M, Galdzicki Z, Castellino FJ: The amino acid residue at sequence position 5 in the conantokin peptides partially governs subunit-selective antagonism of recombinant N-methyl-D- aspartate receptors. J Biol Chem (2001) 276(29):26860-26867.
29. Skolnick P, Boje K, Miller R, Pennington M, Maccecchini ML: Noncompetitive inhibition of N-methyl-D-aspartate by conantokin-G: Evidence for an allosteric interaction at polyamine sites. J Neurochem (1992) 59(4):1516-1521.
30. Blandl T, Prorok M, Castellino FJ: NMDA-receptor antagonist requirements in conantokin-G. FEBS Lett (1998) 435(2-3):257- 262.
31. Chandler P, Pennington M, Maccecchini ML, Nashed NT, Skolnick P: Polyamine-like actions of peptides derived from conantokin-G, an N-methyl-D-aspartate (NMDA) antagonist. J Biol Chem (1993) 268(23):17173-17178.
32. Layer RT, Wagstaff JD, White HS: Conantokins: Peptide antagonists of NMDA receptors. Curr Med Chem (2004) 11(23):3073-3084. • An excellent review summarizing the pharmacological properties of conantokins, including analgesic, antiepileptic and neuroprotective activities.
33. Skolnick P, Zhou L-M, Chandler P, Nashed NT, Pennington M, Maccecchini M-L: Pharmacology and toxicology: Basic and clinical aspects. In: Direct and Allosteric Control of Glutamate Receptors. Palfreyman MG, Reynolds IJ, Skolnick P (Eds), CRC Press, Boca Raton (1994):155-165.
34. Williams AJ, Ling G, McCabe RT, Tortella FC: Intrathecal CGX-1007 is neuroprotective in a rat model of focal cerebral ischemia. NeuroReport (2002) 13(6):821-824.
35. Williams AJ, Ling G, Berti R, Moffett JR, Yao C, Lu XM, Dave JR, Tortella FC: Treatment with the snail peptide CGX-1007 reduces DNA damage and alters gene expression of c-fos and bcl-2 following focal ischemic brain injury in rats. Exp Brain Res (2003) 153(1):16-26.
36. Lu XC, Williams AJ, Wagstaff JD, Tortella FC, Hartings JA: Effects of delayed intrathecal infusion of an NMDA receptor antagonist on ischemic injury and peri-infarct depolarizations. Brain Res (2005) 1056(2):200-208. • Describes the mechanism of neuroprotection produced by conantokin-G by targeting NMDA receptors.
37. Haack JA, Rivier J, Parks TN, Mena EE, Cruz LJ, Olivera BM: Conantokin T: A γ-carboxyglutamate-containing peptide with N-methyl- D-aspartate antagonist activity. J Biol Chem (1990) 265(11):6025-6029.
38. White HS, McCabe RT, Armstrong H, Donevan S, Cruz LJ, Abogadie FC, Torres J, Rivier JE, Paarman I, Hollmann M, Olivera BM: In vitro and in vivo characterization of conantokin-R, a selective NMDA antagonist isolated from the venom of the fish-hunting snail Conus radiatus. J Pharmacol Exp Therap (2000) 292(1):425-432.
39. Jimenez EC, Donevan S, Walker C, Zhou L-M, Nielsen J, Cruz LJ, Armstrong H, White HS, Olivera BM: Conantokin-L, a new NMDA receptor antagonist: Determinants for anticonvulsant potency. Epilepsy Res (2002) 51(1-2):73-80.
40. Gowd KH, Twede V, Watkins M, Krishnan KS, Teichert RW, Bulaj G, Olivera BM: Conantokin-P, an unusual conantokin with a long disulfide loop. Toxicon (2008) 52(2):203-213.
41. Sheng Z, Dai Q, Prorok M, Castellino FJ: Subtype-selective antagonism of N-methyl-D-aspartate receptor ion channels by synthetic conantokin peptides. Neuropharmacology (2007) 53(1):145-156.
42. Kosinski CM, Standaert DG, Counihan TJ, Clemens RS, Kerner JA, Daggett LP, Velicelebi G, Penney JB, Young AB, Landwehrmeyer GB: Expression of N-methyl-D-aspartate receptor subunit mRNAs in the human brain: Striatum and globus pallidus. J Comp Neurol (1998) 390(1):63-74.
43. Counihan TJ, Landwehrmeyer GB, Standaert DG, Kosinski CM, Scherzer CR, Daggett LP, Velicelebi G, Young AB, Penney JB: Expression of N-methyl-D-aspartate receptor subunit mRNA in the human brain: Mesencephalic dopaminergic neurons. J Comp Neurol (1998) 390(1):91-101.
44. Bulaj G, West PJ, Garrett JE, Watkins M, Zhang MM, Norton RS, Smith BJ, Yoshikami D, Olivera BM: Novel conotoxins from Conus striatus and Conus kinoshitai selectively block TTX-resistant sodium channels. Biochemistry (2005) 44(19):7259-7265.
45. Zhang MM, Fiedler B, Green BR, Catlin P, Watkins M, Garrett JE, Smith BJ, Yoshikami D, Olivera BM, Bulaj G: Structural and functional diversities among μ-conotoxins targeting TTX-resistant sodium channels. Biochemistry (2006) 45(11):3723-3732.
46. Zhang MM, Green BR, Catlin P, Fiedler B, Azam L, Chadwick A, Terlau H, McArthur JR, French RJ, Gulyas J, Rivier JE et al: Structure function characterization of μ-conotoxin KIIIA, an analgesic, nearly irreversible blocker of mammalian neuronal sodium channels. J Biol Chem (2007) 282(42):30699-30706.
47. Yao S, Zhang MM, Yoshikami D, Azam L, Olivera BM, Bulaj G, Norton RS: Structure, dynamics, and selectivity of the sodium channel blocker μ-conotoxin SIIIA. Biochemistry (2008) 47(41):10940-10949.
48. Schroeder CI, Ekberg J, Nielsen KJ, Adams D, Loughnan ML, Thomas L, Adams DJ, Alewood PF, Lewis RJ: Neuronally selective μ-conotoxins from Conus striatus utilize an α-helical motif to target mammalian sodium channels. J Biol Chem (2008) 283(31):21621-21628.
49. Green BR, Catlin P, Zhang MM, Fiedler B, Bayudan W, Morrison A, Norton RS, Smith BJ, Yoshikami D, Olivera BM, Bulaj G: Conotoxins containing nonnatural backbone spacers: Cladistic-based design, chemical synthesis, and improved analgesic activity. Chem Biol (2007) 14(4):399-407.
50. Terlau H, Olivera BM: Conus venoms: A rich source of novel ion channel-targeted peptides. Physiol Rev (2004) 84(1):41-68.
51. Imperial JS, Silverton N, Olivera BM, Bandyopadhyay P, Sporning A, Ferber M, Terlau H: Using chemistry to reconstruct evolution: On the origins of fish-hunting in venomous cone snails. Proc Am Phil Soc (2007) 151(2):185-200.
52. Terlau H, Shon KJ, Grilley M, Stocker M, Stuhmer W, Olivera BM: Strategy for rapid immobilization of prey by a fish-hunting marine snail. Nature (1996) 381(6578):148-151.
53. + channel. J Biol Chem (1998) 273(1):33-38.
54. + channels by κ-conotoxin PVIIA is state dependent. J Gen Physiol (1999) 114(1):125-140.
55. + channel. J Biol Chem (2000) 275(32):24639-24644.
56. Huang X, Dong F, Zhou HX: Electrostatic recognition and induced fit in the κ-PVIIA toxin binding to Shaker potassium channel. J Am Chem Soc (2005) 127(18):6836-6849.
57. Zhang SJ, Yang XM, Liu GS, Cohen MV, Pemberton K, Downey JM: CGX-1051, a peptide from Conus snail venom, attenuates infarction in rabbit hearts when administered at reperfusion. J Cardiovasc Pharmacol (2003) 42(6):764-771.
58. Lubbers NL, Campbell TJ, Polakowski JS, Bulaj G, Layer RT, Moore J, Gross GJ, Cox BF: Postischemic administration of CGX-1051, a peptide from cone snail venom, reduces infarct size in both rat and dog models of myocardial ischemia and reperfusion. J Cardiovasc Pharmacol (2005) 46(2):141-146. • Validates the use of κ-conotoxin PVIIA as a cardioprotective agent by using two animal models of myocardial ischemia.
59. + channels are mutually exclusive. Biophys J (2004) 86(1 Pt 1):191-209.
60. + channels. J Biol Chem (2003) 278(4):2177-2183.
61. Ferber M, Al-Sabi A, Stocker M, Olivera BM, Terlau H: Identification of a mammalian target of κM-conotoxin RIIIK. Toxicon (2004) 43(8):915-921.
62. + channel antagonist. Biochemistry (2004) 43(27):8625-8635.
63. + channels. J Biol Chem (2005) 280(22):21246- 21255.
64. Terlau H, Olivera B, Dendorfer A: Postischemic administration of K M-RIIIK, a conopeptide interacting with votage gated K+ channels reduces infarct size in rat hearts in vivo. In: Joint Meeting of the German Society of Physiology and the Federation of European Physiological Societies Acta Physiologica (2006) 186: Suppl 650.
65. + channels: κM-conotoxins and cardioprotection. Doctoral Dissertation, (University of Utah/Department of Biology, Salt Lake City, UT, USA) (2007).
66. Dy CY, Buczek P, Imperial JS, Bulaj G, Horvath MP: Structure of conkunitzin-S1, a neurotoxin and Kunitzfold disulfide variant from cone snail. Acta Crystallogr D Biol Crystallogr (2006) 62(Pt 9):980-990.
67. Bayrhuber M, Vijayan V, Ferber M, Graf R, Korukottu J, Imperial J, Garrett JE, Olivera BM, Terlau H, Zweckstetter M, Becker S: Conkunitzin-S1 is the first member of a new Kunitz-type neurotoxin family. Structural and functional characterization. J Biol Chem (2005) 280(25):23766- 23770.
68. v1.6 channel and nAChR subtypes defines a new superfamily of conotoxins. Biochemistry (2006) 45(27):8331-8340.
69. + channels. J Biol Chem (2008) 283(34):23026-23032.